Tsodikov, Faina http://orcid.org/0000-0001-5264-3073
Schechter, Meir http://orcid.org/0000-0002-5071-3143
Goldsmith, Rebecca
Peleg, Lilach
Baloush-Kleinman, Vered
Rozenberg, Aliza
Yanuv, Ilan
Gimelfarb, Yuri http://orcid.org/0000-0002-5059-7648
Mosenzon, Ofri
Endevelt, Ronit
Article History
Received: 2 June 2021
Revised: 12 December 2021
Accepted: 4 January 2022
First Online: 12 January 2022
Competing interests
: OM declares Advisory Board from Novo Nordisk, Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, Novartis, AstraZeneca, BOL Pharma; Research grant support through Hadassah Hebrew University Hospital from Novo Nordisk, AstraZeneca; Speaker’s Bureau from AstraZeneca, Novo Nordisk, Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, Jansen. All other authors declare no conflict of interest.
: Authors confirm that the submitted study was conducted according to GCP and ICHH. The study was approved by the IRB of the Ministry of Health, Israel.